Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils.
Concomitant use of allogeneic donor granulocyte transfusions and amphotericin B in febrile neutropenic recipients may be limited by the increased incidence of respiratory distress. In vitro effects of amphotericin B and AmBisome were compared on polymorphonuclear leukocyte (PMN) aggregation from PMNs isolated from granulocyte-colony-stimulating factor (G-CSF)/dexamethasone-mobilized allogeneic donors. Six allogeneic donors were mobilized with G-CSF (600 microg subcutaneously) and dexamethasone (8 mg orally) 12 hours before leukopheresis. AmBisome was associated with significantly less PMN aggregation (100 microM [microg/mL]) (0.33% +/- 0.33% vs 54.33% +/- 5.82%; P <.001) than amphotericin B. Furthermore, with the addition of the PMN agonist, FMLP, AmBisome was also associated with significantly less aggregation (100 microM [microg/mL]) (18.67% +/- 1.45% vs 54.67% +/- 2.4%; P <.001). In summary, these studies demonstrate that liposomal amphotericin is associated with significantly less in vitro PMN aggregation than amphotericin B and could possibly be administered concomitantly with mobilized allogeneic PMN infusions.
Sulis
Maria Luisa
ML
Department of Pediatrics, Children's Hospital of New York, Columbia University, New York, NY 10032, USA.
Van de Ven
Carmella
C
Henderson
Theresa
T
Anderson
Lauren
L
Cairo
Mitchell S
MS
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001782:Blood Donors; D002449:Cell Aggregation / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007937:Leukapheresis; D017708:Leukocyte Transfusion; D008081:Liposomes / Q000008:administration & dosage; D009181:Mycoses / Q000209:etiology / Q000628:therapy; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000008:administration & dosage* / Q000009:adverse effects; D009503:Neutropenia / Q000150:complications / Q000628:therapy; D009504:Neutrophils / Q000187:drug effects*
D000935:Antifungal Agents; D005938:Glucocorticoids; D008081:Liposomes; D016179:Granulocyte Colony-Stimulating Factor; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003907:Dexamethasone; D000666:Amphotericin B